Neurocrine Biosciences, Inc. (NBIX)

139,22 +0,33 (+0,24%) In data: 01:53PM EDT. Mercato aperto.

Neurocrine Biosciences, Inc.

12780 El Camino Real
San Diego, CA 92130
United States
858 617 7600
https://www.neurocrine.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 1.400

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Kevin C. Gorman Ph.D.	CEO & Director	2,05M	N/D	1958
Mr. Matthew C. Abernethy	Chief Financial Officer	1,06M	N/D	1980
Dr. Jude Onyia Ph.D.	Chief Scientific Officer	1,22M	N/D	1964
Mr. Kyle W. Gano Ph.D.	Chief Business Development & Strategy Officer	990,12k	N/D	1973
Dr. Eiry Wyn Roberts M.D.	Chief Medical Officer	1,12M	4,15M	1964
Jane Sorensen	Head of Investor Relations	N/D	N/D	N/D
Mr. Darin M. Lippoldt Esq.	Chief Legal Officer & Corporate Secretary	921,01k	2,98M	1966
Ms. Julie S. Cooke	Chief Human Resources Officer	N/D	N/D	1966
Mr. Eric S. Benevich	Chief Commercial Officer	805k	295,52k	1965
Mr. David Warren Boyer	Chief Corporate Affairs Officer	N/D	N/D	1980

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Governance aziendale

L'ISS Governance QualityScore di Neurocrine Biosciences, Inc. al 29 aprile 2024 è 2. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 1; diritti degli azionisti: 3; retribuzione: 4.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.